Participation in clinical trials for new blood cancer treatments should reflect the patient population who will use the treatment. Yet Black Americans continue to be underrepresented across most clinical trials – even for diseases like multiple myeloma, the most common blood cancer diagnosed in the Black community.

Please join us to learn more about the need for diversity in clinical trial participation and what changes are necessary to make these trials more accessible to all patients.